GUEST COLUMNISTS

  • The Evolution Of Biomarker-driven Approaches To Clinical Trials

    Greater understanding of the specific and varying genetic bases for cancers has provided greater opportunities for clinical trials to take advantage of patient genetic variability for recruitment and segmentation purposes. In this article, historic data provide insights into the evolution and future of biomarker use in precision medicine.

  • Starting A Career In Clinical Research: 7 Things We Wish We Knew

    The clinical research industry is facing a talent shortage that could become acute in the next decade. A main contributor to this shortage is a lack of focused intervention at every level to identify the skills, behaviors, and knowledge that will enable motivated candidates to begin and mature their careers in the industry. 

  • New Approaches In Patient Tracking For The Rare Disease Sector

    While we have seen exponential growth in the effort to develop drugs to treat rare diseases in the 30 years since the Orphan Drug Act was introduced, unique challenges remain. Awareness of rare diseases is often low among stakeholders including physicians, healthcare providers, payers, and even patients themselves; trial protocols and regulatory pathways may be unclear, especially for investigational rare disease drugs that are first-in-class; and data on disease incidence, onset, progression, and burden are often limited.

  • Janssen’s Patient-centric Approach To Psychiatric Disease Management

    Diseases as complex as those of the brain require an equally complex approach, centered on the unique needs, goals, and circumstances of the individual patients, as well as the loved ones who support them. Listening, empathizing, understanding — these basic human interactions will have a critical role in our ability to reach our goal and deliver transformational medical innovations.

  • Pandemic Accelerates Expanding Role Of Real-World Evidence In FDA Medical Device Submissions

    By forcing the FDA to become comfortable with the use of real-world data in order to authorize COVID-19 diagnostic tests, the pandemic may have unintentionally forced the agency to reflect in a more pragmatic way on what characteristics of real-world evidence (RWE) it believes are essential for data integrity and what level of uncertainty it can tolerate in connection with RWE.

  • How EMD Serono Is Bringing Diverse Patient Voices Together

    The pandemic has created an opportunity to address some of the causes underlying clinical care inequities. And while combatting these issues will take time, much can be done by first addressing the gap for minorities in clinical trials. This is a topic I am passionate about both personally and professionally as a female Hispanic chief medical officer.

  • Are You At Risk For An FDA ClinicalTrials.gov-Related Monetary Penalty?

    The FDA has historically not initiated formal actions to enforce the statutory requirements to register and provide clinical trial data to the ClinicalTrials.gov data bank. However, industry is now on notice that the FDA is about to change its approach.

  • Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma’s Playbook

    Rezolute, a small company working in the rare pediatric disease space, is developing a new therapeutic option specifically for patients with congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Connecting and partnering with advocacy groups and physicians is paramount in the company's clinical trial execution. 

CLINICAL TRIAL WHITE PAPERS

  • Braving The Complexities Of Immuno-Oncology Trials

    Immuno-oncology trials are increasing in prevalence and, for many reasons, are much more complex than standard clinical trials. Learn how partnering with an experienced central lab can alleviate these challenges, create efficiencies and save researchers time and expense.

  • Lessons Learned When Implementing A Risk Management Program

    The design and implementation of risk management programs can be challenging. This white paper uncovers key lessons learned from our experience with over 120 RiskMAPs and REMS programs - which spans various therapeutic areas and targeted risks.

  • Pharmacy Services In A Phase I Clinical Research Unit

    This white paper discusses the role of the pharmacy in a modern day Phase I clinical research unit and its role in understanding the safety and pharmacology of a drug before Phase II can begin.

  • Compensating Participants In Clinical Research: Current Thinking

    New research on how people make decisions about research participation, and new approaches to the question of payments and compensation to participants, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.

  • Bringing Real World Evidence Into Clinical Research

    Life sciences companies are embracing the essential roles that real world data (RWD) and the generation of real world evidence (RWE) play in the development of new treatments for patients.This paper will explore three areas where RWD and RWE are being applied to improve the design and execution of clinical studies.

  • Mitigating Inherent Risks In Global Sample Processing

    The global demand for specialized sample processing has grown dramatically however despite the rising need, research teams continue to struggle to obtain high-quality laboratory support services to perform sample processing. Learn how innovative flow cytometry fast turnaround and monitored, specialized processing can help safeguard samples.

CLINICAL TRIAL APP NOTES & CASE STUDIES

  • Seven Reasons To Consider A Just In Time Manufacturing Approach For Your Clinical Trial Supplies

    Evaluating the potential that modern drug production methods offer, in terms of increased supply chain optimization and agility, is essential for sponsors. Read Almac’s article to find out how Just in Time Manufacturing can help deliver a flexible, continuous, and cost-effective clinical supply chain operation.

  • Resting Heart Rate Measurement With Philips Health Band In Adults With Lifestyle-Related Chronic Disease

    The Philips Health band (PHB) is a wrist-worn wearable device that leverages accelerometry and photoplethysmography (PPG) sensors to deliver sleep, cardiology, respiratory, and energy expenditure (EE) endpoints. In this study the resting heart rate (RHR) was evaluated for clinical relevance in adults with (or at risk) for life-style related chronic disease using the Philips Health band. RHR has been identified as a risk factor and a modifiable treatment outcome.

  • Getting Every Detail Right – With No Time To Think About How

    With a customer racing to beat a competitor to registration with last patient out to database lock in two weeks, this CRO was able to step in and take charge and the study was completed on schedule.

  • Lucky CRAs. Getting Automated To-Do Lists For Targeted SDV

    Data managers at Lotus Clinical Research used to spend hours each week building reports to identify the patients and forms that needed Source Data Verification (SDV) at the next site monitoring visit. To tackle the problem, Veeva Vault EDC introduced QuickView, a dynamic interface that optimizes the display of data by function, allowing users to focus on what matters most.

  • Enrollment Goals Exceeded Through High Touch, High Tech For A Dermatology Study Of Adolescent Patients

    UBC was selected by a large biopharmaceutical company to manage a U.S.- based Phase IV randomized, placebo controlled clinical trial of patients with severe acne. As a result of UBC’s innovative services, not only was the enrollment goal achieved, but it was exceeded by 60%

  • The Accelerated Evolution Of Clinical Trials In A Pandemic Environment

    To explore the impact of the current environment on clinical trial management, we surveyed professionals involved in clinical trials at biopharmaceutical companies, medical device companies, and CROs based around the world. The research results provide valuable insight into how the COVID-19 pandemic is changing the way clinical trials are being conducted, and identifies the key challenges and opportunities surrounding these changes.

CLINICAL LEADER CONTENT COLLECTIONS

20_10_CL_ClinicalTrialsPandemic_Ebook_300x200

 

When the pandemic hit, many hospitals, clinics, and sponsor companies were caught by surprise. The effort to protect patients and keep them away from clinics put many trials in jeopardy. Amidst the chaos, sponsors and regulators were able to scramble and keep many trials going while considering the safety and needs of participants. In this collection of articles from Clinical Leader, learn how companies not only survived, but created new policies that will be tomorrow’s best practices.

More Content Collections

FOCUS ON PATIENTS

  • Janssen’s Patient-centric Approach To Psychiatric Disease Management

    Diseases as complex as those of the brain require an equally complex approach, centered on the unique needs, goals, and circumstances of the individual patients, as well as the loved ones who support them. Listening, empathizing, understanding — these basic human interactions will have a critical role in our ability to reach our goal and deliver transformational medical innovations.

  • Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma’s Playbook

    Rezolute, a small company working in the rare pediatric disease space, is developing a new therapeutic option specifically for patients with congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Connecting and partnering with advocacy groups and physicians is paramount in the company's clinical trial execution. 

  • 4 Practical Ways To Improve The Patient Experience In Clinical Trials

    Stakeholders have recognized the need for patients and advocates to have a seat at the table and be the central focus in enterprise approaches, commercialization, and research and development. How can we gather as much data in as few studies as possible? And in doing this, how can we acknowledge the impact that taking part in a trial has on the patients we are working to help?

EMBRACING DIVERSITY & INCLUSION